| Adverse Event Category, No. (%)a . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Adverse event | 112 (72.3%) | 120 (76.9%) | 232 (74.6%) |
| Grade 3 or 4 adverse event | 13 (8.4%) | 16 (10.3%) | 29 (9.3%) |
| Adverse event related to study drug | 16 (10.3%) | 6 (3.8%) | 22 (7.1%) |
| Grade 3 or 4 adverse event related to study drug | 1 (0.6%) | 0 | 1 (0.3%) |
| Serious adverse event | 12 (7.7%) | 11 (7.1%) | 23 (7.4%) |
| Serious adverse event related to study drug | 0 | 0 | 0 |
| Adverse event leading to study drug discontinuation | 7 (4.5%) | 3 (1.9%) | 10 (3.2%) |
| Death during study | 1 (0.6%) | 2 (1.3%) | 3 (1.0%) |
| Adverse Event Category, No. (%)a . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Adverse event | 112 (72.3%) | 120 (76.9%) | 232 (74.6%) |
| Grade 3 or 4 adverse event | 13 (8.4%) | 16 (10.3%) | 29 (9.3%) |
| Adverse event related to study drug | 16 (10.3%) | 6 (3.8%) | 22 (7.1%) |
| Grade 3 or 4 adverse event related to study drug | 1 (0.6%) | 0 | 1 (0.3%) |
| Serious adverse event | 12 (7.7%) | 11 (7.1%) | 23 (7.4%) |
| Serious adverse event related to study drug | 0 | 0 | 0 |
| Adverse event leading to study drug discontinuation | 7 (4.5%) | 3 (1.9%) | 10 (3.2%) |
| Death during study | 1 (0.6%) | 2 (1.3%) | 3 (1.0%) |
Abbreviations: FTC/TDF,emtricitabine/tenofovir disoproxil fumarate; PI,protease inhibitor; 3TC/ABC,lamivudine/abacavir.
| Adverse Event Category, No. (%)a . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Adverse event | 112 (72.3%) | 120 (76.9%) | 232 (74.6%) |
| Grade 3 or 4 adverse event | 13 (8.4%) | 16 (10.3%) | 29 (9.3%) |
| Adverse event related to study drug | 16 (10.3%) | 6 (3.8%) | 22 (7.1%) |
| Grade 3 or 4 adverse event related to study drug | 1 (0.6%) | 0 | 1 (0.3%) |
| Serious adverse event | 12 (7.7%) | 11 (7.1%) | 23 (7.4%) |
| Serious adverse event related to study drug | 0 | 0 | 0 |
| Adverse event leading to study drug discontinuation | 7 (4.5%) | 3 (1.9%) | 10 (3.2%) |
| Death during study | 1 (0.6%) | 2 (1.3%) | 3 (1.0%) |
| Adverse Event Category, No. (%)a . | FTC/TDF + PI/r (N = 155) . | 3TC/ABC + PI/r (N = 156) . | Total (N = 311) . |
|---|---|---|---|
| Adverse event | 112 (72.3%) | 120 (76.9%) | 232 (74.6%) |
| Grade 3 or 4 adverse event | 13 (8.4%) | 16 (10.3%) | 29 (9.3%) |
| Adverse event related to study drug | 16 (10.3%) | 6 (3.8%) | 22 (7.1%) |
| Grade 3 or 4 adverse event related to study drug | 1 (0.6%) | 0 | 1 (0.3%) |
| Serious adverse event | 12 (7.7%) | 11 (7.1%) | 23 (7.4%) |
| Serious adverse event related to study drug | 0 | 0 | 0 |
| Adverse event leading to study drug discontinuation | 7 (4.5%) | 3 (1.9%) | 10 (3.2%) |
| Death during study | 1 (0.6%) | 2 (1.3%) | 3 (1.0%) |
Abbreviations: FTC/TDF,emtricitabine/tenofovir disoproxil fumarate; PI,protease inhibitor; 3TC/ABC,lamivudine/abacavir.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
